Financings in Brief: Neoprobe:
This article was originally published in The Gray Sheet
Executive Summary
Neoprobe: Expects to net $15 mil. from redemption of series E warrants issued during its November 1992 initial public offering. More than 99% of the 2.3 mil. warrants were presented for exercise before they expired Nov. 12, Neoprobe says. The series E warrants had an exercise price of $6.50. Proceeds will be used to develop Neoprobe's RIGS surgical and therapy products for breast cancer, as well as the firm's RIGS/ACT activated cellular therapy product, the firm says...